Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Prevention Trials (by Organ Site)

Abstract PR06: Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia

Nagi B. Kumar, Julio Pow-Sang, Kathleen M. Egan, Philippe A. Spiess, Shohreh Dickinson, Raoul Salup, Mohamed Helal, Jerry McLarty, Christopher R. Williams, Fred Schreiber, Said Sebti, Aslam Kazi, Loveleen Kang, Gwen Quinn, Tiffany Smith, Karen Diaz, Ganna Chornokur, Theresa Crocker and Michael J. Schell
Nagi B. Kumar
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julio Pow-Sang
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Egan
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe A. Spiess
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shohreh Dickinson
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raoul Salup
2James A. Haley V.A. Hospital, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Helal
3University of South Florida College of Medicine, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry McLarty
4LSUHSC – Feist-Weiller Cancer Center, Shreveport, LA,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher R. Williams
5University of Florida, Jacksonville, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Schreiber
6Watson Clinic - Center for Cancer Care & Research, Lakeland, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Said Sebti
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aslam Kazi
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loveleen Kang
2James A. Haley V.A. Hospital, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gwen Quinn
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffany Smith
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Diaz
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ganna Chornokur
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa Crocker
2James A. Haley V.A. Hospital, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Schell
1Moffitt Cancer Center & Research Institute, Tampa, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6215.PREV-14-PR06 Published October 2015
  • Article
  • Info & Metrics
Loading
Abstracts: Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research; September 27 - October 1, 2014; New Orleans, LA

Abstract

Importance: In recent years, several studies have suggested effectiveness of green tea catechins in prostate cancer (PCa) chemoprevention. With the exception of one trial from Italy, this has not been further tested in a randomized trial setting in high-risk men with atypical small acinar proliferation (ASAP) or high grade prostatic intraepithelial neoplasia (HGPIN).

Objective: To determine whether the daily consumption of a standardized formulation of green tea catechins (Polyphenon E) supplement for 1 year reduces the rate of progression to PCa in men, diagnosed with HGPIN or ASAP. Additional objectives were to evaluate tolerance, lower urinary tract symptoms (LUTS) and quality of life (QOL).

Design, setting and participants: A randomized, double-blinded trial was conducted from September 2008 to March 2014 at medical centers in the US targeting 97 men diagnosed HGPIN or ASAP, randomized to treatment (n=49) or control arm (n=48). Supplement or placebo was initiated within 3 months of initial biopsy and continued for 1 year.

Intervention: Participants were block randomized by baseline diagnosis and study site to receive Polyphenon E (PolyE), a decaffeinated, standardized green tea catechin mixture, the main component of which is (−)-epigallocatechin-3-gallate (EGCG) at a dose of 400 mgs EGCG per day (200 mgs twice a day [BID]), or placebo.

Main outcomes and measures: Rate of progression to PCa at one year in men treated with PolyE or placebo following diagnosis of HGPIN or ASAP; evaluation of tolerance, LUTS and QOL.

Results: Overall, we did not observe a difference in the number of men who progressed to PCa in one year in the Poly E (4/49) arm compared to placebo arm(6/48). Secondary analyses of patients reaching a definitive endpoint revealed that among men with baseline diagnosis of HGPIN, a greater number progressed to ASAP or PCa in the placebo arm (10/25) compared to the PolyE arm (3/26; P<0.05). Interestingly, this result was largely driven by the fact that a significantly greater number of subjects with baseline HGPIN progressed to ASAP in the placebo arm (5/25) compared to men in the PolyE arm (0/26; P <0.05). In men with baseline diagnosis of ASAP, the rate of cancer diagnosis at the end of intervention were similar in both study arms. Men in the PolyE group treated for one year demonstrated a significant decrease in serum tPSA compared to those in the placebo group (-0.90 ng/mL;(95%CI:-1.67, -0.12; P<0.05). No significant differences in tolerance, LUTS or QOL were observed between the two groups.

Conclusions and Relevance: Daily intake of a standardized, decaffeinated catechin mixture containing 400 mgs EGCG (200 mgs BID) for 1 year is well tolerated and appears to produce chemoprevention effects in the early stages (HGPIN to ASAP) of prostate carcinogenesis. These findings should be confirmed in a phase III clinical trial prior to recommending use in clinical settings.

Trial Registration: Clinical Trials.gov Identifier: NCT00596011

Acknowledgement: The research study was funded by the National Institute of Health- National Cancer Institute R01 CA12060-01A1. We acknowledge the contributions of Anthony M. Neuger, Domenico Coppola, Binglin Yue, (Moffitt Cancer Center); Kyle Anderson (Minneapolis VA Medical Center, Minneapolis, MN); Eduard Trabulsi (Jefferson Medical College, Philadelphia, PA); Tajammul Fazili (Overton Brooks VA, Shreveport, LA); Edward Giovanucci (Harvard University); Gregory Zagaja (University of Chicago, Chicago, IL); Shahnjayla Connors (University of Washington, St. Louis, MO); Folake Odedina (University of Florida). External Data Monitoring Board: Omer Kucuk, (Emory University), Phyllis Bowen (Retired), and Steven Clinton (Ohio State University).

Citation Format: Nagi B. Kumar, Julio Pow-Sang, Kathleen M. Egan, Philippe A. Spiess, Shohreh Dickinson, Raoul Salup, Mohamed Helal, Jerry McLarty, Christopher R. Williams, Fred Schreiber, Said Sebti, Aslam Kazi, Loveleen Kang, Gwen Quinn, Tiffany Smith, Karen Diaz, Ganna Chornokur, Theresa Crocker, Michael J. Schell. Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia. [abstract]. In: Proceedings of the Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2014 Sep 27-Oct 1; New Orleans, LA. Philadelphia (PA): AACR; Can Prev Res 2015;8(10 Suppl): Abstract nr PR06.

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Prevention Research: 8 (10 Supplement)
October 2015
Volume 8, Issue 10 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract PR06: Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract PR06: Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia
Nagi B. Kumar, Julio Pow-Sang, Kathleen M. Egan, Philippe A. Spiess, Shohreh Dickinson, Raoul Salup, Mohamed Helal, Jerry McLarty, Christopher R. Williams, Fred Schreiber, Said Sebti, Aslam Kazi, Loveleen Kang, Gwen Quinn, Tiffany Smith, Karen Diaz, Ganna Chornokur, Theresa Crocker and Michael J. Schell
Cancer Prev Res October 1 2015 (8) (10 Supplement) PR06; DOI: 10.1158/1940-6215.PREV-14-PR06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract PR06: Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia
Nagi B. Kumar, Julio Pow-Sang, Kathleen M. Egan, Philippe A. Spiess, Shohreh Dickinson, Raoul Salup, Mohamed Helal, Jerry McLarty, Christopher R. Williams, Fred Schreiber, Said Sebti, Aslam Kazi, Loveleen Kang, Gwen Quinn, Tiffany Smith, Karen Diaz, Ganna Chornokur, Theresa Crocker and Michael J. Schell
Cancer Prev Res October 1 2015 (8) (10 Supplement) PR06; DOI: 10.1158/1940-6215.PREV-14-PR06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Prevention Trials (by Organ Site)

  • Abstract A16: Molecular tracking of metformin chemoprevention in a 300-person ALLIANCE randomized placebo controlled trial in women at high risk for triple-negative breast cancer
  • Abstract A18: Personalized prevention of colorectal cancer trial
Show more Clinical Prevention Trials (by Organ Site)

Prostate and Other Genitourinary Tract Cancers

  • Abstract PR04: Aspirin, NSAIDs, and risk of prostate cancer: Results from the REDUCE study
  • Abstract A20: A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis
Show more Prostate and Other Genitourinary Tract Cancers

Prostate and Other Genitourinary Tract Cancers: Oral Presentations - Proffered Abstracts

  • Abstract PR04: Aspirin, NSAIDs, and risk of prostate cancer: Results from the REDUCE study
  • Abstract A20: A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis
  • Abstract PR06: Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia
Show more Prostate and Other Genitourinary Tract Cancers: Oral Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement